Propanc Biopharma plans to acquire a digital asset financial company with a market value below its net asset value.

On November 4, according to Globenewswire, digital asset financial company Propanc Biopharma (NASDAQ: PPCB) announced a strategic plan aimed at acquiring digital asset management (DAT) companies currently trading at a market value to net asset value (MNAV) ratio below their actual value. The company's management believes that acquiring undervalued digital asset technology (DAT) companies is an excellent opportunity to strengthen Propanc's balance sheet, achieve asset diversification, and create long-term shareholder value. These DAT companies typically hold large amounts of mainstream digital assets such as bitcoin and ethereum on their balance sheets. Propanc's board of directors and executive team are currently evaluating potential acquisition targets and developing a due diligence framework to assess balance sheet strength, digital asset holdings, and operational synergies.